ChemPartner PharmaTechLtd Gestione

Gestione criteri di controllo 1/4

ChemPartner PharmaTechLtd's Il CEO è Swee Lian Woo, nominato in Jan2024, ha un mandato di meno di un anno. possiede direttamente 4.56% delle azioni della società, per un valore di CN¥ 107.88M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 2.9 anni.

Informazioni chiave

Swee Lian Woo

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	4.6%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	3yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Swee Lian Woo (63 yo)

less than a year

Mandato

Mr. Swee Lian Woo is President of Perfect (China) Co., Ltd. He is Director of RRTC, Inc. He serves as General Manager and Chairman of Chempartner Pharmatech Co., Ltd. since January 10, 2024.He was Chairma...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jian Xu	Board Secretary	2.9yrs	CN¥1.44m	Nessun dato
Zhenjia Chen	Vice President	1.5yrs	CN¥1.78m	Nessun dato
Swee Lian Woo	GM & Chairman	less than a year	Nessun dato	4.56% CN¥ 142.6m

1.5yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di 300149 non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Swee Lian Woo	GM & Chairman	less than a year	Nessun dato	4.56% CN¥ 142.6m
Xin Hui	Director	6.3yrs	CN¥360.00k	Nessun dato
Rong Yu	Director	less than a year	Nessun dato	Nessun dato
Dachao Zhang	Chairman of the Supervisory Board	3.2yrs	Nessun dato	Nessun dato
Zhicheng Guo	Independent Director	4.1yrs	CN¥80.00k	Nessun dato
Shi Xin Fan	Director	2.9yrs	CN¥1.03m	Nessun dato
Xianzhong Wang	Independent Director	3.2yrs	CN¥80.00k	0.00030% CN¥ 9.4k
Jiahui Qi	Supervisor	6.3yrs	Nessun dato	0.0084% CN¥ 263.6k
Ling Yang	Independent Director	1.8yrs	CN¥80.00k	Nessun dato
Man Ngar Wong	Employee Supervisor	1.6yrs	Nessun dato	Nessun dato

3.0yrs

Durata media

53.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300149 sono considerati esperti (durata media dell'incarico 3 anni).

ChemPartner PharmaTechLtd Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

Less than half of directors are independent

Recent updates

ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)

ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)

New minor risk - Share price stability

Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)

Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Tate & Lyle plc (LSE:TATE) completed the acquisition of Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

First quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 1Q 2021)

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022

Less than half of directors are independent

Tate & Lyle plc (LSE:TATE) signed an agreement to acquire Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for $237 million.

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)

Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021

Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)

Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020

New 90-day low: CN¥12.64

New 90-day low: CN¥12.66

Investor sentiment deteriorated over the past week

New 90-day low: CN¥14.46

New 90-day low: CN¥18.29

Third quarter earnings released

New 90-day high - CN¥23.98

First half earnings released

Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥22.71

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media